[go: up one dir, main page]

MX2022016591A - Moléculas de anticuerpo contra april y usos de las mismas. - Google Patents

Moléculas de anticuerpo contra april y usos de las mismas.

Info

Publication number
MX2022016591A
MX2022016591A MX2022016591A MX2022016591A MX2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A
Authority
MX
Mexico
Prior art keywords
antibody molecules
molecules against
april
against april
treat
Prior art date
Application number
MX2022016591A
Other languages
English (en)
Inventor
Zachary Shriver
Gregory Babcock
James R Myette
Boopathy Ramakrishnan
Hedy Adari-Hall
Jill Yarbrough
Asher Schachter
Karthik Viswanathan
Andrew M Wollacott
Mohit Mathur
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2022016591A publication Critical patent/MX2022016591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Se describen moléculas de anticuerpo que se unen específicamente a APRIL. Las moléculas de anticuerpo se pueden usar para tratar, prevenir y/o diagnosticar trastornos, tal como la nefropatía por IgA.
MX2022016591A 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas. MX2022016591A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043558P 2020-06-24 2020-06-24
US202063091002P 2020-10-13 2020-10-13
US202163136950P 2021-01-13 2021-01-13
US202163195527P 2021-06-01 2021-06-01
PCT/US2021/038924 WO2021262999A1 (en) 2020-06-24 2021-06-24 Antibody molecules to april and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016591A true MX2022016591A (es) 2023-04-20

Family

ID=77022225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016591A MX2022016591A (es) 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas.

Country Status (10)

Country Link
EP (1) EP4172206A1 (es)
JP (1) JP2023531722A (es)
KR (1) KR20230042273A (es)
AU (1) AU2021297315A1 (es)
BR (1) BR112022026639A2 (es)
CA (1) CA3187823A1 (es)
MX (1) MX2022016591A (es)
PH (1) PH12023550198A1 (es)
TW (1) TW202216195A (es)
WO (1) WO2021262999A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1254337A1 (zh) 2015-11-25 2019-07-19 Visterra, Inc. April的抗体分子及其用途
EP4514381A1 (en) * 2022-04-25 2025-03-05 Visterra, Inc. Antibody molecules to april and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
HK1254337A1 (zh) 2015-11-25 2019-07-19 Visterra, Inc. April的抗体分子及其用途
KR102777127B1 (ko) 2016-08-02 2025-03-07 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도

Also Published As

Publication number Publication date
TW202216195A (zh) 2022-05-01
JP2023531722A (ja) 2023-07-25
BR112022026639A2 (pt) 2023-05-09
KR20230042273A (ko) 2023-03-28
PH12023550198A1 (en) 2024-06-24
CA3187823A1 (en) 2021-12-30
EP4172206A1 (en) 2023-05-03
AU2021297315A1 (en) 2023-02-02
WO2021262999A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
CL2021000039A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796)
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
ZA202208280B (en) Antibody molecules to c5ar1 and uses thereof
MX2023010751A (es) Nuevos usos de derivados de piperidinil-indol.
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
MX375683B (es) Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas.
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201891594A1 (ru) Антитела к il-17c
MX2022016591A (es) Moléculas de anticuerpo contra april y usos de las mismas.
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos
PH12021552414A1 (en) Anti fgf23 antibody
MY201744A (en) Binding polypeptides and methods of making the same
CO2021000349A2 (es) Moléculas de anticuerpo de componente de complemento 5 y sus usos
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
RU2013131293A (ru) Способ лечения аллергодерматозов, сопровождающихся ксерозом